Directorate Change

4 December 2014

Immunodiagnostic Systems Holdings plc

Board Change

Immunodiagnostic Systems Holdings plc ("IDS" or "the Company" or "the Group"), a leading solution provider to the clinical laboratory diagnostic market, announces that on 4 December 2014 Chris Yates, Chief Financial Officer,  gave notice of his intention to leave the Company at the end of his 12 month notice period, or as may be agreed otherwise.

Dr Burkhard Wittek, Non-Executive Chairman, said:

"I would like to thank Chris for his important contribution to IDS over the last few years. He has played a valuable role in the development of the business and I wish him well in his future endeavours."

For further information:

About Immunodiagnostic Systems Holdings PLC

The Group's vision is to be a leading solution provider to the clinical laboratory diagnostic market. IDS's strategy is focused on developing, internally and through partnership, its automated assay menu for its proprietary automated immunoassay analyser, the IDS-iSYS system. Internally the Group is focused on developing an endocrinology excellence menu and externally IDS works with partners to develop assay panels in complementary indication fields. The Group sells its products primarily in the clinical laboratory market across a range of customers from reference laboratories to physician office laboratories. IDS has field sales forces in certain European countries, including France and Germany, the United States and Brazil and works with distributors in other markets including China, Italy and Spain.